Silymarin Dosage Guide: Protocols, Calculator & Safety

Silymarin stacks naturally with several other hepatoprotective and metabolic-support agents. The goal of stacking is mechanistic complementarity, not redundancy — combining agents that hit different nodes in hepatic injury and recovery.

Tier 1: Classical liver-support stack.

• TUDCA 250–500 mg BID: bile acid with FXR-ligand activity, ER-stress reduction, and direct mitochondrial membrane stabilization. The mechanistic complement to silymarin: silymarin protects the hepatocyte plasma membrane and cytosolic redox balance, TUDCA protects the ER and mitochondria. Excellent evidence base in cholestatic liver disease, emerging evidence in NAFLD. No meaningful drug interactions. This is the single highest-value silymarin partner.
• N-acetylcysteine 600–1200 mg/day: cysteine-donor substrate for glutathione synthesis. Silymarin upregulates GCL (rate-limiting enzyme), NAC provides the cysteine substrate. The two are mechanistically complementary and well-tolerated together. Gold-standard for acetaminophen hepatotoxicity alone but also supportive in chronic hepatic contexts.
• Glutathione (liposomal or acetyl-L-glutathione) 250–500 mg/day: the master intracellular antioxidant that silymarin replenishes and upregulates. Direct supplementation is a reasonable adjunct, though NAC is often more cost-effective for raising hepatic GSH.
• Alpha-lipoic-acid 300–600 mg/day: mitochondrial antioxidant with both water- and lipid-soluble activity, GSH regeneration, and mild insulin-sensitizing effect. Adds the mitochondrial node that silymarin addresses less directly.

Tier 2: Metabolic / NAFLD-specific stack.

• Berberine 500 mg BID-TID: activates AMPK, improves insulin sensitivity, reduces hepatic de novo lipogenesis, and has direct effects on hepatic lipid metabolism. Strongly complementary to silymarin in NAFLD: silymarin addresses oxidative and inflammatory nodes, berberine addresses the metabolic driver (insulin resistance and hepatic fat accumulation). Separate by 2+ hours for GI tolerance.
• Choline (phosphatidylcholine or choline bitartrate) 500–1000 mg/day: essential for VLDL packaging and export of triglycerides from hepatocytes. Choline deficiency is a direct cause of hepatic steatosis; supplementation corrects the lipid export defect. Pairs well with silymarin for NAFLD.
• Inositol (myo-inositol + D-chiro-inositol) 2–4 g/day: insulin-sensitizing, improves hepatic and systemic insulin signaling. Valuable in NAFLD with concurrent PCOS or metabolic syndrome.
• Astaxanthin 8–12 mg/day: highly lipid-soluble carotenoid antioxidant with emerging evidence in NAFLD for reduction of hepatic lipid peroxidation.
• Vitamin E (mixed tocopherols, 400 IU/day): standard-of-care in non-diabetic NASH per AASLD guidelines. Combines well with silymarin (both are lipid-phase antioxidants in the hepatocyte) but limit duration to 12–24 months given emerging concerns about prostate cancer risk in men at higher doses with chronic use.

Tier 3: Polyphenol / longevity stack.

• Quercetin 500 mg/day (preferably phytosome form): flavonol with overlapping anti-inflammatory and antioxidant mechanisms. Silymarin and quercetin share some phase-II metabolism; potential for mild competition at UGT enzymes but not clinically problematic.
• Curcumin (phytosome or Meriva) 500–1000 mg/day: polyphenol with overlapping hepatoprotective and anti-inflammatory activity. Good stacking partner. Curcumin has its own weak CYP effects; combine with attention to concurrent prescription drug metabolism.
• Resveratrol 500 mg/day or pterostilbene 100 mg/day: stilbene SIRT1 activators. Complementary longevity mechanism to silymarin's hepatoprotection.
• Hydroxytyrosol 10–25 mg/day or high-polyphenol EVOO: Mediterranean-diet polyphenol matrix. Particularly relevant in NAFLD context where Mediterranean dietary pattern is the evidence-based lifestyle intervention.
• Apigenin 50–100 mg/day: flavone with CD38 inhibition (preserves NAD+ levels) and anti-inflammatory activity.

Tier 4: Hepatitis-specific adjuncts (under clinician oversight).

• If chronic hepatitis C: direct-acting antivirals (sofosbuvir-velpatasvir, glecaprevir-pibrentasvir) are curative and silymarin is adjunctive at most. Continue silymarin through DAA therapy; it has no interference with DAA pharmacokinetics.
• If chronic hepatitis B: tenofovir or entecavir are first-line antiviral therapy. Silymarin is adjunctive for hepatic protection.
• If alcoholic liver disease: alcohol cessation is primary. Silymarin + NAC + thiamine + folate + multivitamin is a reasonable adjunct regimen alongside abstinence and nutritional rehabilitation.

Stacks to approach with caution.

• Any cocktail of 5+ botanical hepatoprotectants simultaneously: mechanistic overlap and opportunity for unpredictable interactions. Prefer a focused 2–4 ingredient stack built around evidence rather than throwing every liver-support botanical at the problem.
• High-dose vitamin A (>10,000 IU retinol/day): vitamin A is itself hepatotoxic at chronic high doses. Do not combine with silymarin and claim both are "liver support." Mixed carotenoids are safe; retinol needs dose vigilance.
• Kava-kava, comfrey, chaparral, germander, greater celandine, pyrrolizidine alkaloid-containing botanicals: known hepatotoxins. Do not combine with silymarin under a "more is better" reasoning; the hepatotoxin is the problem, not silymarin's response to it.
• High-dose green tea catechins (>800 mg EGCG/day from extracts): rare hepatotoxicity signal with high-dose EGCG extracts. Culinary green tea is fine; high-dose catechin extracts with silymarin would confuse hepatic monitoring.

Timing within the stack. Silymarin with meals (especially fat-containing meals, which improve absorption of the flavonolignan-phospholipid complex). NAC 30+ minutes before food for best absorption. TUDCA with meals. Berberine with meals (to reduce GI side effects). Choline and inositol with meals. This integrates naturally with standard supplement-with-meal timing.

Monitoring on stacks. Baseline comprehensive metabolic panel (liver enzymes, bilirubin, albumin), fasting glucose, HbA1c, lipid panel. Recheck liver enzymes at 4–8 weeks and then every 3–6 months during chronic use. FibroScan elastography annually in high-risk NAFLD patients. Discontinue individual agents if adverse signals develop (liver enzyme rise >2x baseline, persistent GI intolerance, new fatigue, or allergic symptoms).

Silymarin dosing is well-established across four decades of clinical research. The key variables are (1) product standardization, (2) formulation (standard extract vs. phytosome vs. IV), and (3) indication.

Standard oral doses by indication.

• General daily liver support (healthy user, preventive): 150–200 mg standardized silymarin (70–80% silymarin) BID, total 300–400 mg/day.
• NAFLD / NASH / MAFLD / MASH (outpatient, ambulatory): 280–420 mg silymarin BID-TID, or silybin-phosphatidylcholine (phytosome) 240 mg BID delivering superior absorbed silibinin. Typical trial doses: Loguercio used 94 mg silybin + 194 mg phosphatidylcholine + 30 IU vitamin E TID (Realsil); Navarro 2019 used 420 mg silymarin TID.
• Chronic hepatitis C (historical indication, now superseded by DAAs): Fried 2012 tested 420 and 700 mg silymarin TID — null result at ALT endpoint. Not a recommended contemporary indication.
• Alcoholic liver disease, cirrhosis: Ferenci used 420 mg silymarin/day in 3 divided doses — dose at which survival benefit was observed in alcoholic cirrhosis.
• Drug-induced liver injury prevention (methotrexate, isoniazid, antiretrovirals): 420 mg silymarin/day or silybin-phosphatidylcholine 240 mg BID.
• Type 2 diabetes, metabolic syndrome: 200 mg silymarin TID (Huseini protocol).
• Amatoxin poisoning: IV silibinin dihydrogensuccinate 20 mg/kg/day in 4 divided infusions for 48–72 hours under hospital supervision. This is not an outpatient protocol. Oral silymarin is not sufficient for acute amatoxin poisoning.

Formulation considerations.

• Standardized silymarin extract (70–80% silymarin with ≥30% silibinin): baseline form, oral bioavailability ~0.7–7.5%. Cost-effective for general support. Most appropriate for beginner and maintenance use.
• Silybin-phosphatidylcholine phytosome (Siliphos, IdB1016, Realsil): 4–10 fold increase in silibinin Cmax and AUC. Preferred for NAFLD, NASH, and therapeutic indications. Higher cost (2–4x standardized extract).
• Silymarin dihydrogensuccinate (Legalon): European pharmaceutical-grade standardized extract. Well-characterized bioavailability. Prescription in Germany and some EU countries.
• Silibinin dihydrogensuccinate IV (Legalon SIL): FDA orphan drug for amatoxin poisoning. Hospital-use only, not outpatient.

Timing. With meals, especially meals containing some fat (10+ g). The fatty matrix improves absorption of the flavonolignan-phospholipid complex and also buffers mild GI side effects. For BID dosing: breakfast and dinner. For TID dosing: breakfast, lunch, dinner. Avoid concurrent administration within 2 hours of oral iron supplements (minor non-heme iron absorption reduction).

Duration and cycling. Continuous daily dosing is the evidence-aligned pattern. Ferenci's survival-benefit cohort took silymarin continuously for mean 41 months. NAFLD trials use 6–12+ month continuous courses. There is no rationale for cycling silymarin in the same way as some herbal adaptogens; it is a maintenance agent. For drug-induced liver injury prevention: continue throughout the course of the hepatotoxic medication plus 4–8 weeks after discontinuation.

Dose titration. Start at the lower end of the indication-specific range for the first 1–2 weeks (150 mg silymarin BID) to assess GI tolerance, then titrate to target. For phytosome forms, start at 240 mg once daily for the first week, then BID.

Ceiling dose. Oral silymarin doses of 1400 mg/day (highest arm of Fried 2012) were tolerated without significant adverse events. There is no rationale to exceed this. For phytosome forms, 720 mg/day (240 mg TID) is the practical upper bound of typical clinical use.

Special populations.

• Pediatric: limited data. Small clinical series in pediatric NAFLD and hepatitis use weight-based dosing (5–10 mg/kg/day silymarin). Not a routine recommendation without pediatrician oversight.
• Elderly: standard adult doses. Monitor for GI tolerance and drug interactions (polypharmacy is common and silymarin's weak CYP inhibition may become clinically relevant).
• Pregnancy: reassure moderate dietary and traditional use; avoid high-dose phytosome or IV forms without obstetric oversight.
• Hepatic impairment: no dose adjustment needed. Silymarin is indicated, not contraindicated, in hepatic impairment.
• Renal impairment: no dose adjustment needed.
• Chronic statin users: standard doses are fine; monitor for new myalgia given weak OATP inhibition modestly elevating statin levels.

Practical product-selection notes.

• Verify the label specifies silymarin percentage (70–80%) and silibinin percentage (ideally ≥30%).
• Avoid "milk thistle seed powder" products without standardization — these are weak and poorly characterized.
• For therapeutic intent: choose a phytosome-formulated product (Siliphos, Realsil, Silybin Advanced) with specified silibinin content per serving.
• For general support: a well-standardized 80% silymarin extract from a USP-verified or NSF-certified manufacturer is adequate.
• Brands: Thorne, Life Extension, Nature's Way (Thisilyn), Jarrow Formulas, NOW Foods, Solgar, Pure Encapsulations, Designs for Health. Avoid "proprietary blend" products where silymarin content is not specified.

Integration with prescription therapy. Silymarin is compatible with virtually all prescription medications with the noted minor CYP and OATP effects. It is particularly compatible with: statins, metformin, GLP-1 agonists, SGLT2 inhibitors, antihypertensives, antidepressants (SSRIs, SNRIs, bupropion), antiviral therapy (HCV DAAs, HBV nucleos(t)ide analogs), and chemotherapy in most regimens. Coordinate with the prescribing physician for narrow-therapeutic-index drugs (warfarin, cyclosporine, tacrolimus, phenytoin, digoxin) — monitoring rather than avoidance is typically sufficient.

Titration of stacked ingredients. When building the intermediate or advanced stack, add one ingredient at a time with 1–2 weeks between additions. This allows identification of the cause of any GI intolerance or adverse signal and avoids the "everything at once" pattern that makes troubleshooting impossible.